196,012 research outputs found
Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study
No full textAim To investigate the role of body mass index (BMI) and weight in the long-term efficacy of etanercept in patients with psoriasis. Methods Medical records were retrospectively analysed. Extracted data included weight, BMI, comorbidities and psoriasis area severity index (PASI). Patients were stratified by weight (<80kg or 80kg) and BMI (healthy, BMI 22 - 24.99kg/m(2); overweight, BMI 25 - 29.99kg/m(2); obese, BMI 30kg/m(2)). Results The study included 66 patients. Body weight had no effect on etanercept efficacy. There was a significant reduction in etanercept efficacy in obese patients (n=12) compared with healthy weight (n=33) or overweight (n=21) patients. Conclusion Obesity has a negative effect on the efficacy of etanercept in psoriasis
Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice
No full textobjective to investigate the efficacy and safety outcomes of combination therapy used to optimize etanercept treatment in patients with psoriasis treated in real-life clinical practice.methods data from patients presenting with psoriasis, treated initially with etanercept monotherapy, were analysed retrospectively. patients subsequently treated with combination therapy were further analysed. the psoriasis area and severity Index (PASI) score was recorded for all patients receiving comedication; a subjective pain score was recorded in those with psoriatic arthritis receiving comedication after 12, 24 and 48weeks' treatment and thereafter at 6-month intervals.results from the database of 400 patients treated with etanercept, 37 patients (18 male; 19 female; mean age 59.43years) underwent combination therapy due to lack of efficacy. patients received mostly short-term (range 4-34weeks) comedication with corticosteroids, cyclosporine, methotrexate, nonsteroidal anti-inflammatory drugs, acitretin or sulphasalazine. there were significant reductions in the mean PASI score from baseline at all timepoints. there were also significant reductions in the mean pain VAS score from baseline at all timepoints in patients with psoriatic arthritis. the drug survival rate was 59.6% over a mean duration of 323weeks of etanercept treatment. the safety profile of combination therapy was satisfactory.conclusions short-term comedication in combination with etanercept may optimize treatment options and improve long-term drug survival in patients with psoriasis
Type III juvenile pityriasis rubra pilaris: A successful treatment with infliximab [12]
No full text[No abstract available
Using distributional models for studying the influence of school textbooks in children bias
No full textPrevalence and management of panic attacks during infliximab infusion in psoriatic patients
No full textBACKGROUND:
Psoriasis is a chronic, inflammatory skin disease associated with anxiety and depression. Infliximab (IFX) is a human/mouse chimeric anti-TNF-α antibody effective in the treatment of psoriasis.
OBJECTIVE:
The aim of this study was to evaluate the prevalence of panic disorders in psoriatic patients during IFX infusions.
METHODS:
A retrospective study was performed on patients affected with psoriasis who were treated with IFX from 2002 to 2011 at a single center. Panic disorders were defined using the clinical criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition. A population of dermatological patients under treatment with IVG, rituximab, apheresis, intravenous corticosteroids and antibiotics was considered as the control group.
RESULTS:
A total of 141 patients were evaluated. Of these, 6 (4.25%) experienced panic attacks during the infusion; 16 (11.3%) had a medical history of panic attack and of those 5/16 (31%) experienced panic attacks during IFX infusion. In the control group panic attacks were not recorded.
CONCLUSION:
We describe 6 cases of patients in whom panic attacks were triggered by IFX infusion. Premedication with oral benzodiazepine and a slow rate of infusion is recommended
High-dose initiation of etanercept in plaque psoriasis and psoriatic arthritis: an italian experience
No full text
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab
No full textPsoriasis affects about 2-3% of the Caucasian population. Biologics such as infliximab, etanercept, adalimumab and ustekinumab are efficacious treatments of plaque-type psoriasis. Critical to monitoring drug efficacy and safety is availability of long-term data. Despite the chronic nature of psoriasis, to date limited long-term clinical data have been available, as challenges are inherent in conducting a long-term analysis. With increasing time, it is more likely that the number of patients discontinuing treatment will also increase, due to loss of efficacy, adverse events or loss to follow-up. Interpretation of these data becomes confounded when one must consider missing data. Several approaches to analysing long-term data exist, and each accounts for missing data differently
- …
